ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.

<h4>Background</h4>We sought to assess the relative effects of individual anaplastic lymphoma kinase (ALK) inhibitors for the treatment of non-small cell lung cancer (NSCLC).<h4>Methods</h4>We searched MEDLINE, Embase, Cochrane CENTRAL, and grey literature (July 23, 2019) for...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-01-01
Series:	PLoS ONE
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0229179&type=printable
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
by: Jesse Elliott, et al.
Published: (2020-01-01)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-10-01)

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data
by: Vera Damuzzo, et al.
Published: (2025-05-01)

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01)

Identifying the Intergenic ALK Fusion LOC388942‐ALK as a Driver of Non–Small Cell Lung Cancer
by: Xiaoqian Zhai, et al.
Published: (2025-04-01)

Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer
by: Xie J, et al.
Published: (2025-04-01)

Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience
by: Claudia Parisi, et al.
Published: (2024-12-01)

Modern treatment of ALK-positive non-small cell lung cancer
by: D. A. Kharagezov, et al.
Published: (2022-06-01)

Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
by: Mingyue Wang, et al.
Published: (2025-02-01)

Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
by: Suma Devaraj, et al.

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
by: Seema Chugh, et al.
Published: (2025-02-01)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
by: Luca Mastrantoni, et al.
Published: (2024-01-01)

Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
by: Weizhen SUN, et al.
Published: (2024-11-01)

Safety of Lorlatinib in Patients with Unresectable Advanced <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India
by: Ullas Batra, et al.
Published: (2025-08-01)

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01)

Global research trends on ALK-TKIs in non-small cell lung cancer: a bibliometric analysis
by: Yafeng Liu, et al.
Published: (2025-08-01)

Organizing pneumonia in ALK+ non-small cell lung cancer treated with ceritinib: a case report
by: Xiao Lin, et al.
Published: (2025-07-01)

Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
by: Dafeng Guo, et al.
Published: (2022-12-01)

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
by: Federica Malighetti, et al.
Published: (2024-12-01)

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
by: Yue Lu, et al.
Published: (2021-11-01)

CT-based radiomics analysis for predicting EGFR and ALK mutational status in non‑small cell lung cancer
by: Ruimin He, et al.
Published: (2025-07-01)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023-11-01)

Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer
by: Magdalena Zaborowska-Szmit, et al.
Published: (2024-11-01)

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer
by: Zhengyu Zha, et al.
Published: (2025-04-01)

Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer
by: Sang‐Min Park, et al.
Published: (2025-04-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China
by: Guangming Tian, et al.
Published: (2025-05-01)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
by: Marine Sivignon, et al.
Published: (2020-01-01)

Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.
by: Liang Fan, et al.
Published: (2014-01-01)

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer
by: Josephina Sampson, et al.
Published: (2024-12-01)

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
by: Kaili Huang, et al.
Published: (2025-04-01)

Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4–ALK+ metastatic non-small cell lung adenocarcinoma
by: Khyati Somayaji Dasika, et al.
Published: (2025-04-01)

AlkTango reveals a role for Jeb/Alk signaling in the Drosophila heart
by: G Wolfstetter, et al.
Published: (2025-05-01)

The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors.
by: Eun-Jeong Yu, et al.
Published: (2024-01-01)

A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01)

Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
by: Fengzhi Zhao, et al.
Published: (2015-01-01)

Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer
by: Yanqing Pan, et al.
Published: (2025-05-01)

Correction: Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer
Published: (2020-05-01)

Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancer
by: Dülger Onur, et al.
Published: (2025-01-01)

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01)